Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering's diagnostic sales down 6%:

This article was originally published in Clinica

Executive Summary

German company Schering's contrast media sales fell 6% to DM 1,194 million ($838 million) in the first nine months of 1995. The company blames the strong mark together with the withdrawal of its contrast medium, Isovist 280 (see Clinica No 675, p 9). Schering feels that although sales will be lost through the product withdrawal, this may be partially offset by increased sales of other Schering contrast agents. Net profits were down 18% to DM 172 million and total group sales fell 2% to DM 3,499 million. Analysts predict that on current sales performance and forecasts, results for 1996 will not improve on those for 1994.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094155

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel